nebokitug   Click here for help

GtoPdb Ligand ID: 13666

Synonyms: CM-101 | CM101
Compound class: Antibody
Comment: Nebokitug is the INN for an anti-C-C motif chemokine ligand 24 (CCL24) monoclonal antibody (proposed INN list 131, August 2024). It is likely clinical lead CM-101 (ChemomAb Ltd.). CCL24 is a soluble cytokine that is an important regulator of inflammation and fibrosis in human diseases such as primary sclerosing cholangitis (PSC) [1], systemic sclerosis, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). It promotes recruitment and activation of both immune cells and fibroblasts and this combined action induces over-production of extracellular matrix components that underlie fibrosis. Blocking CCL24-mediated signalling, via its receptor CCR3, with CM-101 has demonstrated therapeutic potential in preclinical PSC models [3-4].
No information available.
Summary of Clinical Use Click here for help
CM-101 is in clinical trials to determine potential efficacy in the reduction of fibrosis and cholestasis in patients with primary sclerosing cholangitis (PSC) [2]. It has been granted Orphan Drug designation by the FDA and EMA for this indication and for systemic sclerosis.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06044467 The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects Phase 1 Interventional ChemomAb Ltd.
NCT06037577 Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects Phase 1 Interventional ChemomAb Ltd.
NCT06025851 Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects Phase 1 Interventional ChemomAb Ltd.
NCT04595825 CM-101 in PSC Patients -The SPRING Study Phase 2 Interventional ChemomAb Ltd.